COVID-19 aus Sicht der Kardiologie

Abstract

The SARS-CoV-2 pandemic has rapidly spread around the world and has led to a substantial morbidity and mortality in many countries. Although Corona Virus Disease 19 (COVID-19) is primarily a respiratory tract infection, there is growing evidence that other organs including the cardiovascular system are affected by COVID-19. In this review, we summarize the association of myocardial injury with in-hospital mortality of COVID-19 patients. Furthermore, we discuss potential mechanisms of myocardial injury including myocarditis and vascular thrombosis. Last, we review the current evidence on drugs which have been evaluated or are currently tested for the treatment of COVID-19 patients.

Inzwischen mehren sich die Hinweise, dass die Infektion mit SARS-CoV-2 neben schweren Atemwegsinfektionen auch das kardiovaskuläre System betrifft. Diverse Fallberichte weisen auf eine myokardiale Inflammation sowie ein erhöhtes Thromboserisiko im Zusammenhang mit COVID-19 hin. Studien aus vergangenen Jahren und die Erfahrungen aus der aktuellen Pandemiesituation werden folgend zusammengefasst und mögliche Therapien besprochen.

Schlüsselwörter

SARS-CoV-2 - COVID-19 - Myokarditis - thrombotisches Risiko - Remdesivir - Interferon-β

Key words

SARS-CoV-2 - COVID-19 - myocarditis - thrombotic risk - Remdesivir - Interferon-β

• Literatur

• 1 Su S, Wong G, Shi W. et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol 2016; 24: 490-502
• 2 Guo T, Fan Y, Chen M. et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; e201017
• 3 Oudit GY, Kassiri Z, Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009; 39: 618-625
• 4 Caforio AL, Pankuweit S, Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648, 2648a–2648d
• 5 Inciardi RM, Lupi L, Zaccone G. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;
• 6 Tavazzi G, Pellegrini C, Maurelli M. et al Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020; 22: 911-915 . doi:10.1002/ejhf.1828
• 7 Wichmann D, Sperhake JP, Lutgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; M20-2003
• 8 Klok FA, Kruip MJHA, van der Meer NJM. et al Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research 2020; 191: 148-150 . doi:10.1016/j.thromres.2020.04.041
• 9 Creel-Bulos C, Hockstein M, Amin N. et al Acute Cor Pulmonale in Critically Ill Patients with Covid-19. N Engl J Med 2020; 382: e70 . doi:10.1056/NEJMc2010459
• 10 Oxley TJ, Mocco J, Majidi S. et al Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 2020; 382: e60 . doi:10.1056/NEJMc2009787
• 11 Bangalore S, Sharma A, Slotwiner A. et al. ST-Segment Elevation in Patients with Covid-19 – A Case Series. N Engl J Med 2020;
• 12 Ruan Q, Yang K, Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; May 46 (05) 846-848
• 13 Tang N, Li D, Wang X. et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis: JTH 2020; 18: 844-847
• 14 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
• 15 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-1418
• 16 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020;
• 17 Poissy J, Goutay J, Caplan M. et al. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. Circulation 2020;
• 18 Gilead. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19. Im Internet (Stand: 19.06.2020): https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19
• 19 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 – Preliminary Report. N Engl J Med 2020;